Delivery Order SPE2DB22D3009-SPE2DB25FAT61

Award Date 3/19/25
Potential Completion Date 4/9/25
Potential Value $3.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a delivery order with a firm fixed-price pricing type and a ceiling value of $5,762.72. It is for the pharmaceutical product "XOLAIR 150 MG/ML SYRINGE" and has an ultimate completion date of July 7, 2025. The contract is not set aside for any specific business type. Amerisourcebergen Drug Corp holds...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,688.08 firm fixed price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product. The contract has a period of performance through May 28, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,776.12 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a medical product. The contract has an ultimate completion date of May 30, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a $10,010.88 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XOLAIR 150 MG/1.2 ML POWDER VLS, with a performance period ending on June 12, 2025. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical support vehicle...
This federal contract award is a delivery order valued at $10,805.10 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with a period of performance through July 3, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of XOLAIR 150 MG/ML SYRINGEML. The $3,376.16 firm fixed-price delivery order has a completion date of June 4, 2025 and is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a global pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,688.10 fixed-price delivery order is for XOLAIR 150 MG/ML syringes, a pharmaceutical product. The contract has no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as...
This federal contract award was made by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,440.70 delivery order contract is for the supply of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product. The contract is a firm fixed price, non-set-aside award with a period of performance through July 1, 2025. Amerisourcebergen Drug Corp holds a larger $999,999,999.00...
This is a $20,856.25 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 150 MG/1.2 ML POWDER VLS, a pharmaceutical product, with an ultimate completion date of June 27, 2025. The contract is not set-aside and was awarded on June 5, 2025. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery...
This is a federal contract award by the Defense Logistics Agency (DLA), a defense agency, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,805.10 firm-fixed-price delivery order is for XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product. The contract has a completion date of June 20, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB22D3009
    Indefinite Delivery Contract
  • SPE2DB22D3009-SPE2DB25FAT61
    Delivery Order

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $3,337.00 firm fixed-price delivery order contract is for the supply of XOLAIR 150 MG/1.2 ML POWDER VLS, a specialty pharmaceutical product. The contract has an ultimate completion date of April 9, 2025. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 6/18/25, 11:18 AM